Pharvaris N.V.

Pharvaris N.V. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of therapies for rare diseases. The company's primary focus is on the development of PHA121, a small molecule bradykinin B2-receptor antagonist currently in Phase II clinical trial for the treatment of hereditary angioedema (HAE). Additionally, Pharvaris is developing PHVS416, an on-demand, rapid exposure soft capsule for acute HAE attacks, and PHVS719, a prophylactic extended-release tablet for HAE patients. These products are aimed at addressing the unmet medical needs of patients suffering from HAE, positioning the company to generate revenue through the successful commercialization of these therapies.

Products

• PHA121 - Small molecule bradykinin B2-receptor antagonist for HAE

• PHVS416 - On-demand, rapid exposure soft capsule for acute HAE attacks

• PHVS719 - Prophylactic extended-release tablet for HAE patients